Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fotemustine followed by autologous dendritic cell vaccine plus ipilimumab for metastatic melanoma
ACTRN12611001136998Phase 2Recruiting
- Sponsor
- Andrew Nicol
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fotemustine, ipilimumab and autologous dendritic cell vaccine in melanoma, sponsored by Andrew Nicol. Primary endpoints: Overall response and time to progression and Comparison of response rates with historical studies. Started Nov 2011; status: recruiting.
02
Drugs
fotemustineipilimumabautologous dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12611001136998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001136998.